| Outcome Measures: |
Primary: Mean amplitude of glycemic excursions (MAGE) change from baseline by continuous glucose monitoring system (CGMS), 1±3day；112±3d | Secondary: Glycemic variability, continuous overlapping net glycemic action (CONGA) and mean of daily differences (MODD), 1±3day；112±3d|Glucose control, Glycosylated hemoglobin A 1c (HbA1c), FBG, postprandial blood glucose (PBG), -7±3d；112±3d；|oxidative stress markers, plasma concentrations of superoxide dismutase (SOD), malondialdehyde, 8-iso-prostaglandin-F2α (8-iso-PGF2α) and urine concentrations of 8-iso-PGF2α;, 1±3d；28±3d；56±3d；84±3d；112±3d|inflammatory markers, plasma concentrations of interleukin-1(IL-1), interleukin-18(IL-18), adiponectin, toll-like receptor 4(TLR-4) and phosphorylated-nuclear factor-kappaB 65 (pNF-κB 65) in white blood cells, 1±3d；28±3d；56±3d；84±3d；112±3d|endothelial function, plasma total nitric oxide synthase (tNOS), inducible nitric oxide synthase (iNOS), nitric oxide (NO), 1±3d；28±3d；56±3d；84±3d；112±3d|beta-cell function and insulin resistance, homeostasis model assessment-β, homeostasis model assessment -insulin resistance, plasma glucagon, body mass index (BMI), waist-hip ratio, 1±3d；112±3d；|body composition, fat mass, lean tissue, body weight, waist circumference, 1±3d；112±3d | Other: Number of Participants with exenatide or insulin glargine adverse events as a measure of safety and tolerability:, hypoglycemia reaction; blood glucose lower than 3.1mmol/L; nausea, vomiting, diarrhea, anorexia or abdominal pain after exenatide subcutaneous injection., -7±3d；1±3d；7±2d；14±3d；21±2d；28±3d；35±3d；56±3d；84±3d；112±3d|Exploratory Objective assessed by the relationships between oxidative stress and inflammatory markers and MAGE, Whether there is linear correlation between oxidative stress markers and MAGE, and between inflammatory markers and MAGE, and correlation coefficient of each correlation, 1±3d；112±3d
|
